Immunostimulatory monoclonal antibodies for cancer therapy (Q36717901)

15 August 2017

1 reference

title

Immunostimulatory monoclonal antibodies for cancer therapy (English)

1 reference

15 August 2017

1 reference

1 reference

Ignacio Melero, MD-PhD

1

object named as

Ignacio Melero

1 reference

15 August 2017

Sandra Hervas-Stubbs

2

1 reference

15 August 2017

Martin Glennie

3

1 reference

15 August 2017

Drew M Pardoll

4

1 reference

15 August 2017

Lieping Chen

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

15 August 2017

Nature Reviews Cancer

1 reference

15 August 2017

7

1 reference

15 August 2017

95-106

1 reference

15 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2051

15 August 2017

0 references

cites work

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

31 March 2020

1 reference

Mechanisms of immune evasion by tumors

31 March 2020

1 reference

Regulatory T cells, tumour immunity and immunotherapy

31 March 2020

1 reference

Does the immune system see tumors as foreign or self?

31 March 2020

1 reference

The danger model: a renewed sense of self

31 March 2020

1 reference

Tolerogenic dendritic cells

31 March 2020

1 reference

Cancer despite immunosurveillance: immunoselection and immunosubversion

31 March 2020

1 reference

The promise of cancer vaccines

31 March 2020

1 reference

Adoptive immunotherapy for cancer: building on success

31 March 2020

1 reference

Comparing antibody and small-molecule therapies for cancer

31 March 2020

1 reference

31 March 2020

1 reference

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

31 March 2020

1 reference

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

31 March 2020

1 reference

The immunological synapse.

31 March 2020

1 reference

31 March 2020

The B7 family revisited

1 reference

TNF/TNFR family members in costimulation of T cell responses

31 March 2020

1 reference

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

31 March 2020

1 reference

CD28-mediated co-stimulation: a quantitative support for TCR signalling

31 March 2020

1 reference

T-cell regulation by CD28 and CTLA-4.

31 March 2020

1 reference

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

31 March 2020

1 reference

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

31 March 2020

1 reference

Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist

31 March 2020

1 reference

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin

31 March 2020

1 reference

Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28.

31 March 2020

1 reference

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

31 March 2020

1 reference

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

31 March 2020

1 reference

Costimulation of T cells by OX40, 4-1BB, and CD27.

31 March 2020

1 reference

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

31 March 2020

1 reference

Cutting edge: Expression of functional CD137 receptor by dendritic cells

31 March 2020

1 reference

Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor

31 March 2020

1 reference

CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand

31 March 2020

1 reference

Immune responses in 4-1BB (CD137)-deficient mice

31 March 2020

1 reference

Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.

31 March 2020

1 reference

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway

31 March 2020

1 reference

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

31 March 2020

1 reference

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

31 March 2020

1 reference

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

31 March 2020

1 reference

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

31 March 2020

1 reference

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

31 March 2020

1 reference

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

31 March 2020

1 reference

In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses

31 March 2020

1 reference

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

31 March 2020

1 reference

Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo

31 March 2020

1 reference

Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation

31 March 2020

1 reference

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy

31 March 2020

1 reference

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

31 March 2020

1 reference

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

31 March 2020

1 reference

The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells

31 March 2020

1 reference

OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection

31 March 2020

1 reference

Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand

31 March 2020

1 reference

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

31 March 2020

1 reference

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

31 March 2020

1 reference

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

31 March 2020

1 reference

Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts

31 March 2020

1 reference

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

31 March 2020

1 reference

A molecular perspective of CTLA-4 function

31 March 2020

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

31 March 2020

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

31 March 2020

1 reference

Modulation of tryptophan catabolism by regulatory T cells.

31 March 2020

1 reference

Checkpoint blockade in cancer immunotherapy

31 March 2020

1 reference

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

31 March 2020

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

31 March 2020

1 reference

Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb

31 March 2020

1 reference

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

31 March 2020

1 reference

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

31 March 2020

1 reference

Combinatorial cancer immunotherapy

31 March 2020

1 reference

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy

31 March 2020

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

31 March 2020

1 reference

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

31 March 2020

1 reference

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

31 March 2020

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

31 March 2020

1 reference

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

31 March 2020

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

31 March 2020

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

31 March 2020

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

31 March 2020

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

31 March 2020

1 reference

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

31 March 2020

1 reference

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

31 March 2020

1 reference

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

31 March 2020

1 reference

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

31 March 2020

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

31 March 2020

1 reference

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

31 March 2020

1 reference

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

31 March 2020

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

31 March 2020

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

31 March 2020

1 reference

Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells.

31 March 2020

1 reference

Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity

31 March 2020

1 reference

Dendritic cells in a mature age.

31 March 2020

1 reference

CD40/CD154 interactions at the interface of tolerance and immunity

31 March 2020

1 reference

Anti-CD 40 monoclonal antibody.

31 March 2020

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

31 March 2020

1 reference

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

31 March 2020

1 reference

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

31 March 2020

1 reference

IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation

31 March 2020

1 reference

Phase I study of recombinant human CD40 ligand in cancer patients

31 March 2020

1 reference

Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy

31 March 2020

1 reference

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

31 March 2020

1 reference

Eradication of established tumors in mice by a combination antibody-based therapy

31 March 2020

1 reference

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

31 March 2020

1 reference

Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model

31 March 2020

1 reference

Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients

31 March 2020

1 reference

Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells

31 March 2020

1 reference

Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice

31 March 2020

1 reference

TeGenero fiasco prompts regulatory rethink

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

Clinical research. Lessons from a failed drug trial

31 March 2020

1 reference

31 March 2020

1 reference

Cancer immunotherapy: breaking the barriers to harvest the crop

31 March 2020

1 reference

Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC2051

1 reference

15 August 2017

1 reference